SANTA CLARA, Calif. / Oct 16, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2024 after the stock market closes on Monday, Nov. 25. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.
To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
| Last Trade: | US$133.65 |
| Daily Change: | -5.98 -4.28 |
| Daily Volume: | 178,325 |
| Market Cap: | US$38.400B |
October 21, 2024 September 20, 2024 September 09, 2024 August 15, 2024 August 02, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
